The latest data on cases of antibody-mediated pure red cell aplasia
associated with Johnson & Johnson subsidiary Janssen-Cilag's
erythropoietin product Eprex/Erypo (epoetin alfa) have suggested
that measures put in place...
The European Commission has earmarked €13 million from the budget
of the EU's Sixth Research Framework Programme (FP6) (2002-2006) to
promote and facilitate research co-operation with the 13 associated
candidate countries for...
UK developer of medical diagnostics devices Osmetech continued the
strategy to build on its healthcare diagnostics business with the
acquisition this week of the Atlanta-based 'OPTI' product line of
blood gas analysers owned...
Life science company Chiral Quest this week announced that the
non-profit organisation, the Penn State Research Foundation, has
received a US patent covering the compositions of matter and use
for a series of chiral phosphine ligands...
Two British firms, De Novo Pharmaceuticals and Peakdale Molecular,
are to enter into a joint collaboration to exploit their respective
skills in molecular design and chemistry synthesis, writes market
analysts Datamonitor this week.
As the lead story today on In-Pharmatechnologist.com
highlights, the European brain-drain is far from slowing down with
the US continuing to attract researchers and entrepreneurs. A fact
that has had, and will continue to have, a...
Sweden's Biacore International, a specialist in surface plasmon
resonance technologies, has launched its Biacore 3000 GxP (Good
Manufacturing Practice/Good Laboratory Practice) Package, which
will strengthen the system's...
Shareholders at Swiss pharmaceutical company Roche welcomed the
start of a new era as the company summarised recent events,
including the divestment of the vitamins business, at its annual
general meeting yesterday.
Maintaining sterility is a costly process for drug manufacturers,
but US company Pall Corp says it has introduced a new device that
will allow biopharmaceutical producers to make aseptic connections
instantly, reaping large savings...
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...